Effects of Flaxseed on the Glucose Profile in Native American Postmenopausal Women by Korlagunta, Kiranmayi
THE EFFECTS OF FLAXSEED ON THE GLUCOSE 
PROFILE IN NATIVE AMERICAN 
POSTMENOPAUSAL WOMEN
   By
   KIRANMAYI KORLAGUNTA
   Masters in Women’s Studies 
   Alagappa University
Karaikuddi, India
   2001
   Submitted to the Faculty of the
   Graduate College of the
   Oklahoma State University
   in partial fulfillment of
   the requirements for
   the Degree of
   MASTER OF SCIENCE 
   July 2006 
ii
THE EFFECTS OF FLAXSEED ON GLUCOSE 
PROFILE IN NATIVE AMERICAN 
POSTMENOPAUSAL WOMEN
Thesis Approved:
Dr. Bahram H. Arjmandi
Thesis Adviser
Dr.Edralin A. Lucas
Dr. Brenda J. Smith
Dr. A. Gordon Emslie
Dean of the Graduate College
iii
DEDICATION
My thesis is dedicated to three circles of special people in my life. Firstly, to my beloved 
parents for giving me life in the first place, for molding me in to a sensible human being, 
for their effective counseling in my times of despair and for their unconditional love and 
support to pursue my aspirations when they went ahead of the limitations of language, 
culture and countries. Secondly, to my dearly loving friend Dr. K. Andy Prasad, a source 
of my inspiration and who is always there to listen to my complaints, frustration and 
confusions. His compassionate words offered me so much comfort in times of loneliness. 
Thirdly, to the Ford Foundation for its exceptional contribution to the outstanding 
individuals who require absolute access to higher education in the developing countries.
iv
ACKNOWLEDGEMENTS
First of all, I would like to offer my heartfelt gratitude to the almighty who 
bestowed me with this wonderful opportunity to accomplish Masters Degree in 
Nutritional Sciences at Oklahoma State University through a prestigious Ford Foundation 
Fellowship. I also owe my deep gratitude from the down of my heart to the Ford 
Foundation International fellowship crew, and especially to Mr. Berresford (Ford 
President), Ms. Joan Dassin (Ford Executive Director), Ms. Tammy Langan, Ms. Kuckoo 
Rao, Ms. Neera Handa, Mr. Vivek Mansukhani and many others who are involved in 
contributing their part of service to provide financial support to exceptional individuals 
who lack systemic access to higher education in the developing countries. 
No book is ever written alone and no research endeavor is ever taken in solitude. I 
owe my deep gratefulness to many in the accomplishment of my Masters Degree. The 
first and foremost, whom I would like to thank, is Dr.Arjmandi. Life blessed me with the 
opportunity to meet professor Arjmandi. Words can hardly express my deep sense of 
gratitude, indebtedness and reverence for my esteemed teacher and advisor Dr. Arjmandi 
who inspired in me a spirit of dedication, precision and unbiased observation which must 
be cornerstone of every scientific pursuit.
 As my academic advisor, he has been encouraging me all the time to stay paying 
attention on achieving my goal. Working with him, I have learnt that diligence, 
determination and dedication are the three fundamental principles of success in academia 
v
and life as well. His observations and comments helped me to gain knowledge of how to 
conduct clinical and animal trials, write research articles, and present the results of 
research. More importantly, he is so considerate and understanding about me and his 
office always gives a warm and cheerful welcome, which initiates every day a productive 
day. He always reminds me to drink a lot of water, eat more fruits and offers me free 
treats to remain hale and healthy. Without his constant academic encouragement and 
guidance, I could not have completed my research. I am thankful for the invaluable 
support I have received over the months of “thesising” from him, who read my drafts, 
corrected and shaped my conclusions for each segment of the work and work as a whole. 
I appreciate his time and effort put forth towards my research. I would also like to offer 
my special thanks to Dr. Arjmandi’s wife, Ms. Helen for her utmost concern towards me.  
Every year I eagerly look forward for “Thanksgiving Day” to take pleasure in her 
hospitality and to taste her scrumptious turkey and delicious cuisine. 
 Besides my advisor, I also would like to thank the rest of my thesis committee 
Dr. Smith and Dr. Lucas who gave insightful comments and reviewed my work on a very 
short notice.
I would like to thank specially Dr. Lucas, who is most responsible for helping me 
in lab when I was doing experiments. In spite of her busy schedule, she never ever says 
“sorry I can not help you”. I appreciate her lending hand when ever I need. I would like 
to acknowledge my colleagues Dr. Latha Devareddy and Anagha Patade of their 
immense help during the course of my research. Moreover, I am extremely fortunate to 
bless with a friendly and cheerful group of fellow students in the lab. They provided 
enthused and amusing environment which made me never feel home sick. I owe my 
vi
earnest thanks to my lab mates Kavitha Shankavaram, Archana Ellath, Lilly Kamarkar, 
Shirin Hooshmond, Sheau Ching Chai, Sachin Mahajan, and Ryan Howard for being so 
friendly and amicable to me. 
My special thanks go to my brother Dr. Hemanth Kumar and sister in-law 
Manisha for conferring me with a cute little niece Sai Sameera. She is my darling angel. 
Her sweet smile rejuvenates new strength and confidence in me when ever I doubt my 
abilities. I love you Sweetie.
Grateful appreciation goes to my beloved dad and mum for their endless support, 
love and encouragement in all aspects of my life. Special thanks go to my forever good 
friend Dr. Andy Prasad for his unvarying concern towards me. Although he is several 
miles away, still he is an e-mail away to keep my worries stay away. Thank you Dr. Andy 
for all you have done to me.
Last but not the least I extend my heart felt thanks to the participants in our study 





Hypothesis and specific aims...................................................................................4
II. REVIEW OF LITERATURE
Prevalence of diabetes among Native Americans in the United States ...................5
Risk factors for diabetes...........................................................................................7
     Metabolic syndrome and diabetes.......................................................................7
     Obesity and diabetes .........................................................................................11
     Genetics and diabetes........................................................................................14
     Diet and diabetes...............................................................................................17
     Physical inactivity and diabetes ........................................................................19
Prevention and treatment of diabetes .....................................................................21
     Lifestyle modifications ....................................................................................21
    Antidiabetic drugs..............................................................................................25
      Bioactive components that favorably improve glucose profile ………………….27
           Phytoestrogens………………………………………………………………...27
           Lignans………………………………………………………………………..30
           Flaxseed……………………………………………………………………….33
III. MATERIALS AND METHODS
Subject recruitment ...............................................................................................37
Experimental design ..............................................................................................38
Dietary assessment and anthropometric measurements ........................................39
Blood collection and processing ...........................................................................39
Serum analyses ......................................................................................................40
viii






V.  DISCUSSION ........................................................................................................46
REFERENCES ............................................................................................................57




1. Nutrition facts of the study products....................................................52
2. Baseline food intake measured with food frequency questionnaire.....53
3. Food intake during the study by 24hr food recall…………………….54
4. Subject characteristics and anthropometric measurements…………..55
5. Effects of three-month flaxseed supplementation on 




Adult Treatment Panel                             ATP
Behavioral Risk Factor Surveillance                                      BRFS
Body mass index                                                                     BMI
Carbohydrate                                                                           CHO
Cardiovascular disease                                                            CVD
Central nervous system                                                           CNS
Complementary alternative medicine                                     CAM
Estrogen receptor                                                                    ER
Expert Panel                                                                            OEI
Fasting blood glucose                                                              FBS
Food and Drug administration                  FDA
Free fatty acids                                                                        FFA
Generally recognized as safe                                                  GRAS
Glucose transporter                                                                 GLUT
Hepatocyte nuclear factor                                                        HNF
High density lipoprotein                                                          HDL
Homeostasis assessment model of insulin resistance              HOMA-IR
Hormone Replacement Therapy                                              HRT
Hormone sensitive lipase                                                         HSL
xi
Impaired glucose tolerance                                                   IGT
Indian Health Service                                                            IHS
Indulin dependent diabetes mellitus                                      IDDM
Instititutional Review Board                                                 IRB
International Diabetes Foundation                                        IDF
Low density lipoprotein                                                        LDL
Maturity onset diabetes of the youth                                     MODY
Mitochondrial syndrome                                                       MLEAS
National Cholesterol Education Program                             NCEP
National Heart, Lung Blood institute                                   NHLBI
Non insulin dependent diabetes                                           NIDDM 
Non-esterified free fatty acids                                             NEFFA
Proliferator-activated receptor gamma expression              PPAR
Secoisolarirecinol diglucoside                                             SDG
Sex Hormone Binding Globulin                                          SHBG
Strong Heart Study                                                              SHS
Total Triglyceride                                                                TGL
Tumor necrosis factor                                                         TNF




Currently, it is estimated that over 6.3 million men and 8.7 million women in the 
US have diabetes (1). Furthermore, the prevalence of diabetes in US is higher among the 
minority ethnic populations than whites (2) and it is one of the major causes of mortality 
and morbidity in American Indians (3). Approximately 38 to 72% of the Native 
Americans with diabetes are from Oklahoma, South Dakota, North Dakota (2). It is 
excessively affecting women than in men (4) and there are reports (5-8) suggesting that 
age associated with menopause has adverse effect on lipid metabolism and visceral 
obesity which both contributes to the development of insulin resistance and type 2 
diabetes. Although, hormone replacement therapy (HRT) alleviates postmenopausal 
symptoms (9), reduce bone resorption (10), rheumatoid arthritis (11) and schizophrenia 
(12), decrease the risks of cardiovascular disease (CVD) (13)  its effect on carbohydrate 
metabolism is less clear (14). However, maintaining near-normal blood glucose level can 
retard the progression of diabetes-associated macro vascular complications (5, 16). Diet 
restriction, modest exercise, lifestyle interventions, and pharmacotherapy even though 
maintains near normal glycemic profile in diabetics but, sometimes may not succeed (17).
It is also affirmed that prolonged usage of antidiabetic drugs can produce adverse 
effects such as hypoglycemia, weight gain, lactic acidosis and flatulence (18, 19).  
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Therefore, women in developed countries such as those living in the US and West 
European countries can particularly benefit from the use of complimentary and 
alternative medicine (CAM)such as functional foods and dietary supplements in order to 
prevent and/or reduce chronic diseases including but not limited to diabetes, 
cardiovascular disease, and osteoporosis (20).
Although there are a number of studies that have shown the effectiveness of 
lignans and isoflavones in preventing cancer, there are a limited number of studies that 
suggests (20) phytoestrogens may play a role in the treatment of obesity and diabetes. 
Isoflavones, lignans, and coumestans (coumestrol) are the three major classes of 
phytoestrogens. Phytoestrogens are diphenolic compounds found in plants that is similar 
in structure to estrogens found in humans (21, 22).  Phytoestrogens are often considered 
in broader terms, referring to compounds that exert hormonal effects including binding to 
the estrogen receptor (ER), induction of specific hormone-responsive gene products, and 
inhibit stimulation of ER-positive cancer cell growth (21, 22).
Lignans, another type of phytoestrogens, are found in a wide range of plant foods 
with flaxseed being the most concentrated source. When plant lignans and isoflavones 
reach the gut, they are structurally modified by colonic microflora to mammalian lignans 
and isoflavonoids (23). It has been suggested that isoflavones and lignans may have a 
protective role as antipromotional compounds during growth of hormone-dependent 
cancers.  In vitro, lignans and/or isoflavones have been shown to inhibit estrogen 
synthesis, bind to estrogen receptors, and inhibit estradiol-stimulated breast cancer cell 
growth (24-27). Furthermore, lignans may increase sex hormone binding globulin 
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(SHBG) synthesis suggesting that lignans can reduce the biological activity of the sex 
steroid hormones by lowering the concentrations of the free fractions (28). In humans, 
there is some evidence of an association between phytoestrogens, endogenous sex steroid 
hormones, and hormone-dependent cancers (21). Studies (21, 29-31) have reported that 
postmenopausal women with breast cancer, as compared to omnivorous and vegetarian 
controls, excrete lower amounts of urinary lignans.  Significant positive correlations have 
been observed between urinary total lignans, and plasma sex hormone binding globulin 
(SHBG) concentrations, while negative correlations between lignans and plasma free-
estradiol concentrations have been reported (32). In terms of cancer studies, quantity of 
flaxseed consumed or length of dietary flaxseed intervention could be important 
modulators in controlling SHBG secretion and/or estrogen bioavailability and the 
outcome of the investigation.
 There are also a small number of studies in which the positive effects of these 
compounds on carbohydrate metabolism have been investigated (20). In terms of 
wholefood, flaxseed (a rich source of lignans) with estrogenic (33), anti estrogenic (34), 
antitumergic (35), and antioxidant (36) properties may also be effective in normalizing 
blood sugar levels. Therefore, we hypothesized that daily consumption of flaxseed has a 
beneficial effect on the glucose status of postmenopausal women. This hypothesis is 
based on two lines of observations: 1) ovarian hormone deficiency due to menopause 
negatively affect glucose status and increase the risk of diabetes in women (5-8, 2)
lignanic compounds present in flaxseed have resemblance to 17β-estradiol (20) that 
somehow mimics the action of estrogen in improving the glycemic profile of 
postmenopausal women (5-8, 20). To my knowledge, the present study is the first to 
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investigate the effect of intake of ground flaxseed on the glucose status of the Native 
American postmenopausal women.
Hypothesis and specific aims:
The hypothesis of this study was that the daily consumption of flaxseed improves the 
glycemic profile in Native American postmenopausal women. To test this hypothesis we 
had two specific aims as follows:
Aim 1: To determine the extent to which the daily consumption of an 
approximately 30 g flaxseed regimen reduces fasting blood glucose and glycated 
hemoglobin levels in Native American postmenopausal women.
Aim 2:  To determine the extent to which the daily consumption of an 





Prevalence of Diabetes among Native Americans in the US
Diabetes poses a significant health problem in the US. It is estimated that 
6.3million men and 8.3 million women have diabetes (1). Epidemiological data show 
that, diabetes is disproportionately affecting the minority and disadvantaged population in 
the westernized countries (37). Diabetes in the US is 2-6 times greater in minority ethnic 
groups such as Blacks, Hispanics, and Native Americans than whites (38).  
Recent data from Indian Health Service (HIS), Behavioral Risk Factor Surveillance 
System (BRFSS) (39) indicate that the incidence of diabetes is alarming among the 
Native Americans and Alaskan Natives. An epidemiological study (40) also has found 
similar trends in prevalence of diabetes among Native Americans and Alaskan Natives in 
the Atlantic, Alaska, Northern Plains, Southern plains and South West region. The 
findings of this study (40) have indicated a tremendous increase in the number of diabetic 
cases among Native Americans and Alaskan Natives from 43,262 to 64,474 during the 8 
year period of the study (1990-1997). There was also a significant increase in prevalence 
of diabetes by 76% in Alaskan region and 28 to 37% in other regions. Additionally, it 
was documented that the prevalence of diabetes mellitus (DM) was more prevalent in 
women compared to men in all the regions. Forty-nine percent of the diabetic Native 
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Americans and Alaskan Natives were in the age group of 45-64 years.  Since, this study 
was a cross sectional study, the variables for the increased prevalence of diabetes was not 
determined. According to many population–based studies, it was well recognized that the 
adaptable risk factors such as obesity, physical inactivity, and exposure to diabetes in 
uterus increase the risk of diabetes (40, 41). In Native Americans, obesity is highly 
prevalent and this is associated with increased risk of glucose intolerance and diabetes in 
this population (42).
Similar findings were reported by The Strong Heart Study (SHS) (3). The main objective 
of that study was to determine the incidence and factors that increase the risk of diabetes 
in Native American population. The incidence of diabetes increased excessively in Native 
Americans aged between 45 and74 years residing in the regions of Arizona, Oklahoma, 
South and North Dakota. The results indicated that the participants who had higher body 
mass index (BMI), with higher waist to hip ratio, fasting glucose and fasting insulin 
levels at baseline developed diabetes during the study. Also, the participants who had, 
impaired glucose tolerance (IGT), high percentage body fat, total triglyceride (TGL), 
Albumin urea and lower levels of HDL, apoprotein A1 develop diabetes. Additionally, 
the incidence of diabetes was higher in women than men. The results also indicated that 
diabetes was one of the major causes of morbidity and mortality among the Native 
American population (3). Other studies (38, 43)have also identified diabetes to be the  
leading cause for the micro vascular such as neuropathy (44), nephropathy (45) and 
macro vascular complications such cardio myopathy (44) and neuropathy as those seen in 
Native Americans, Mexican Americans, Pima Indians, and Hispanics. The SHS (43)
findings also suggested that diabetes is one of the underlying risk factors for coronary
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heart disease in Native Americans in Oklahoma, South Dakota, North Dakota and with its 
prevalence being greater by 2 to 3 times than other regions of the country. A cohort study 
intended to determine the mortality rate and causes of death in 1012 non-insulin
dependent diabetic Native Americans in Oklahoma showed that the mean annual 
mortality rate was higher in diabetic Oklahoma Indians than the general population with 
and without diabetes(46). The above findings suggest that diabetes is the underlying risk 
factor for the excess mortality and morbidity rates among the Native American 
population.
In short, the reasons for the higher prevalence of diabetes among the minorities are diet 
(e.g. high calorie, high fat diet) (47), life style factors (e.g. physical inactivity, alcohol 
intake) (48, 49), and genetic predisposition (50).
Risk Factors for Diabetes
Metabolic syndrome and diabetes
Non insulin-dependent diabetes (NIDDM) is accelerating in both 
developing and developed nations and disproportionately affecting ethnic groups such as 
Native Americans, African Americans, and Mexican Americans (51). Diabetes is 
associated with both micro-vascular related disorders, e.g. retinopathy, nephropathy, and
neuropathy and macro-vascular complications, e.g. cardiovascular and cerebrovascular 
diseases. Cardiovascular disease (CVD) is the leading cause of death in ethnic groups 
suffering from type 2 diabetes (52). According to the National Survey Data (53), 
metabolic syndrome is the underlying risk factor for the development of CVD and 
NIDDM in the US and is affecting 25% of adults aged between 20 to 70 years and also 
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affecting ethnic groups such as Mexican Americans (32%), African Americans (22%) 
and other racial ethnic groups (20%). Metabolic syndrome is increasing the risk of CVD 
and NIDDM by 2 to 3 fold.
Metabolic syndrome is a group of metabolic abnormalities such as visceral 
obesity, dyslipidaemia, glucose intolerance, impaired fasting glycemia, insulin resistance, 
hypertension that alters glucose and lipid homeostasis and increase the risk of NIDDM 
and CVD (54). In 1988, it was identified by Kim and Reaven (55) that insulin -resistance 
played a key connecting role in the development of metabolic abnormalities and it was 
determined as a major tool to identify individuals at greater risk of CV. Hence, metabolic 
syndrome is, otherwise, known as insulin-resistance syndrome or syndrome X or deadly 
quartet.  A conspicuous increase in the prevalence of metabolic syndrome has been
observed for the past two decades, but at the same time it has been coupled with
worldwide rise in obesity and NIDDM (56). Recently, there is evidence that it is  obesity 
and not  insulin-resistance that plays a detrimental role in influencing other metabolic 
abnormalities that constitute metabolic syndrome (57-60). The Italian Longitudinal Study 
on Aging which was conducted during 1992 to 1996 intended to investigate the affiliation 
between the variables of metabolic syndrome and their impact on the development of 
NIDDM. The study was conducted employing 2295 subjects aged between 65-84 years. 
This was the first study to utilize factor analysis to find out the underlying risk factor for 
the cluster of the metabolic abnormalities. This study recognized new factors such as 
body mass index (BMI), waist circumference (indicators of obesity) that overlie with 
lipid, insulin, blood pressure, glucose factors in both sexes. It was documented that 3.8% 
of men and 6.0% of women who were non diabetic at baseline became diabetic during the 
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four-year period of this study. Body size factor was positively associated with 
development of metabolic syndrome (59). Therefore, it has been recently justified that 
prevalence of obesity and its associated risk factors form the cluster of metabolic 
syndrome (61). 
Accordingly, based on this concept several definitions were framed depending on 
a set of criterion such as visceral obesity, dyslipidaemia, glucose intolerance, impaired 
fasting glycemia, insulin resistance, and hypertension by World Health Organization
(WHO) consultation (62), National Cholesterol Education Program: Adult Treatment 
Panel III (NCEP ATP III) (63), and European Group for the Study of Insulin Resistance
(64). Nevertheless, each definition does have the same opinion on some variables but 
fluctuate on some others. For instance, the NCEP ATP III and International Diabetes 
Federation (IDF) do not include glucose intolerance tolerance and insulin resistance in
the set criteria and mainly emphasize on obesity and its importance in the predisposition 
of many metabolic abnormalities (65). In 2004, a new definition was framed by 
International Diabetes Federation (61), with the following recommendations: “Central 
obesity considered by waist circumference and is ethnicity specific, in addition the 
presence of any two of the following variables for instance raised triglycerides (> 
150mg/dl or 1.7 mmol /L), elevated blood pressure (systolic ≥ 130mm Hg and diastolic ≥
85 mm Hg), raised fasting plasma glucose (≥ 100 mg/dL or 5.6 mmol/L) represent 
metabolic syndrome”. 
The mechanism by which obesity involves in developing insulin-resistance and 
other metabolic abnormalities is by the distribution of fat. The excess accumulation of fat 
in the visceral adipose tissue drains free fatty acids (FFA) into the portal vein (66). This 
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causes increase in the plasma concentration of the FFA leading to ectopic fat storage (fat 
in liver, muscle) (67).Thus elevations of FFA induce insulin resistance by hampering 
hepatic insulin clearance (68).This inhibits insulin mediated uptake of glucose by skeletal 
muscle and causes intramyocellular accumulation of triglycerides and diacylglycerol 
(67). Thus, elevated intramyocellular lipid levels slow down insulin signaling molecules 
and reduce the insulin mediated glucose transport into the muscle by down regulating 
insulin responsive glucose transporter (GLUT4) (69) and inhibits suppression of hepatic 
glucose production and results in hyperglycemia and insulin resistance (70) and
dyslipdaemia  (65). Insulin resistance has been reported to occur due to obesity/ FFA
which  can induce-hypertension by stimulating the sympathetic nervous system leading to 
high concentrations of noradrenalin which is a vasoconstrictor and causes hypertension
(71). Thus, obesity, distribution of fat, concentration of FFA all engage in the a ccrual of
metabolic abnormalities to form metabolic syndrome that leads to pathogenesis of 
NIDDM and CVD. 
More recently, according to IDF (61), there are other components such as 
“tomographic assessment of visceral obesity, liver fat, biomarkers of adipose tissue, 
apolipoprotein B, LDL particle size, endothelial dysfunction, urinary albumin, 
inflammatory markers, and thrombotic markers that influence the development of 
metabolic syndrome, CVD and NIDDM and can be included as part of metabolic 
syndrome criteria”. 
Since, the incidence of metabolic syndrome is escalating rapidly in the world, it 
has been recognized that lifestyle intervention, including low calorie diet, physical 
activity, and weight loss and drug therapies improve all features of metabolic syndrome. 
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Lifestyle modifications are the guiding principles and include  effectual management of 
stress, proper diet, and positive attitude all of which help individuals triumph over this 
syndrome (72).
Obesity and diabetes
Obesity is one of the major risk factors for the development of type 2 diabetes 
(73). Its prevalence is increasing at an alarming rate in both developed and developing 
countries leading to various metabolic disorders such as, hypertension, heart disease, 
gallstones, colon cancer, stroke (74), osteoarthritis, work disability, and sleep apnea, 
insulin resistance (75). It was estimated from the data of 5 prospective cohort studies (76-
80) and the Nurses' Health Study (81) in combination with 1991 national statistics on 
body mass index (BMI) distributions, population size, and overall deaths, 300,000 adult 
Americans die every year due to obesity and its  co-morbidities such as diabetes,
hypertension, dyslipidemia (82, 79). According to data from 2001 Behavioral Risk 
Surveillance system (BRFSS), it was recognized that, along with hike in the prevalence 
of obesity (5.6%), its co morbid condition, diabetes is also increased by 8.2 % from 2000 
to 2001. Unfortunately, the prevalence continues to increase in US adult population, 
irrespective of age, sex, race, and educational background. Therefore, to overcome over 
obesity and its associated risks have become one of the important health challenges in the 
21st century (83). 
Behavioral (84), environmental (85), and genetic factors (86) all influence obesity 
and adversely affect the physical, mental and social well being (87) of the individual. 
Although, there is abundant evidence that obesity alters glucose homeostasis and 
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contributes to insulin-resistance type 2 diabetes,  the underlying mechanism is not clearly 
elucidated (88).One noteworthy finding is that inappropriate anatomical distribution of 
body fat adds to impaired insulin sensitivity, insulin resistance, dyslipidemia, and type 2 
diabetes in both men and women (89).  Usually, 80% of the fat is stored in the 
subcutaneous adipose tissue (SCAT) which is further classified in to abdominal and 
gluteofemoral fat. The remaining is stored in visceral adipose tissue (VAT) and others 
such as retroperitoneal, perirenal and orbital (90).
In obese men, along with accumulation of excess abdominal subcutaneous fat, 
deposition of visceral fat also increases which leads to android or apple-shaped obesity 
(90). In obese women, gluteofemoral subcutaneous fat accumulates more so than men 
and contributes to peripheral obesity or gynoid obesity. The accumulation of visceral fat 
is less compared to obese men, but it is the android obesity in women that leads to 
metabolic complications (90). Studies have demonstrated that, it is the visceral fat that
disrupts  glucose homeostasis by increasing insulin resistance and decreasing insulin 
sensitivity (91-94) because visceral fat cells are less receptive to antilypolytic result of 
insulin.
Insulin, an antilypolytic hormone (95) plays a major role in the utilization of fat 
stored in adipose tissue, and non adipose tissues such as liver and skeletal muscle. It 
facilitates in the uptake of glucose and aids in the formation of glycogen in the liver. It 
also inhibits hepatic gluconeogenesis and glycogenolysis. It also induces lipoprotein 
lipase activity in peripheral tissues and in turn hydrolyses triglycerides (TG) into free 
fatty acids (FFA), monoglycerides and sent to adipose tissue for further re esterification 
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into TG (96). Insulin inhibits the activity of hormone sensitive lipase (HSL) and hampers 
the hydrolysis of TG and inhibits the release of FFA in to the circulation (97).
In obese individuals, due to excess accumulation of fat in the visceral adipose tissue, 
insulin mediated suppression of HSL is seized and increases in the flux of FFA take place 
and drains into hepatocytes through portal vein (98) . Excess drain of FFA in liver 
increases gluconeogenesis, decreases hepatic insulin clearance and decreases glucose 
uptake from blood leading to constant rise in insulin secretion ultimately ends up in 
hyperinsulemic condition resulting in insulin resistance (99). Due to increased HSL 
acitivity in adipose tissue, the size of the adipocytes increases with the accumulation of 
FFA and decreases the storage space by reducing the adipocyte number (100). This 
results in diversion of FFA to extra adipose tissues such as liver, muscles, and heart 
(ectopic fat storage) and produces insulin resistance (100). Apart from the fat distribution, 
there are several other factors such as increased levels of leptin (101), tumor necrosis 
factor-α (TNF –α) (102), plasminogen activator factor inhibitor (PAI-1) (103) and
decreased levels of adinopectin (104) are involved in the development of obesity and 
insulin resistance (105). These factors are known as adipocytokines (hormone-like 
substances) secreted by adipocytes in the adipose tissue (106). Therefore, adipose tissue 
is not only long-term energy storehouse but also is an energetic endocrine organ (107).
Many studies in mice carrying the recessive mutations, obese (ob) and diabetes 
(db), predicted the subsistence of a circulating endocrine hormone that are able to 
communicate information from the periphery to the CNS with regard to the adequacy of 
energy stores (108-110). It has been reported the involvement of leptin, an “ob gene” 
product, in regulation of appetite, energy expenditure and insulin sensitivity by acting on 
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the satiety center of hypothalamus (111). Studies (112-114) demonstrated that a genetic 
mutation on “ob” gene caused hyperphagia in mice, but this condition was reversed when 
leptin was infused (61). The presence of leptin receptors in hypothalamus encoded by 
“db” gene has also been demonstrated in a study by Chen and colleagues (110). Leptin 
secreted from adipocytes reach the hypothalamus crossing the blood brain barrier through 
leptin receptors and activate satiety center by inhibiting the action of neuropeptide Y 
(NPY) a potent stimulator of food intake (115). Studies (116, 117) have demonstrated 
that, a mutation in “db gene” interferes with the signals of leptin to hypothalamus and 
negative feed back mechanism is disrupted resulting in stimulation of NPY causing 
hyperphagia (115). 
A study conducted on Polynesians by Zimmet and colleagues (118), a population 
with high incidence of diabetes and obesity, found that  leptin levels were remarkably 
increased in both sexes and was directly associated with BMI, waist circumference, 
potent indicators of obesity (118). Several animal (119-121) and human (121, 118)
studies also have demonstrated that resistance of hypothamus to leptin, stimulated insulin 
secretion, further contributing to insulin resistance.
To sum up, before getting into intervention approaches, it is important to have 
enhanced understanding about genetic and environmental factors that contributes to 
obesity-induced insulin-resistance and type 2 diabetes.
Genetics and diabetes
Type 2 diabetes is a multifactorial disorder which is influenced by both genetic 
and environmental factors (122).  There are studies that have demonstrated that type 2 
diabetes is affects certain populations more such as the Native Americans (38, 37). This 
15
raised a question that genetics may contribute to type 2 diabetes in these populations
(123). In 1962, it was documented that in periods of surplus availability of food, there 
was an abnormal increase in the secretion of insulin in non-agricultural Native 
Americans. Since, insulin is lipogenic, it resulted in hyperglycemia and excessive 
deposition of fat in this population. This condition favored them during the times of 
famine by utilizing excess fat as a source of energy and fuel to the body (124). Abnormal 
secretion of insulin was assumed to be due to “thrifty gene”. Thus thrifty gene hypothesis 
came in to existence and it proved that some genetic background helped this population 
to live on during times of famine (124). Unfortunately, due to modernization, change in 
the composition of traditional diet, decrease in physical inactivity, excess accessibility to 
food misused thrifty gene hypothesis and added to the development of obesity and 
insulin resistance and ultimately type 2 diabetes (123, 124).  Although, there is 
considerable evidence about the role of genetics in the development of type 2 diabetes,
only 10% of the genetic risk factors have been identified. In view of the fact that, type 2 
diabetes is a polygenic disorder, only a few numbers of cases of NIDDM are due to 
mutations in single gene (122). Maturity onset diabetes of the young (MODY) is the 
common form that results due to single gene mutation. It contributes only 2-5% in the 
development of type 2 diabetes (125). Genetically MODY is considered heterogenous 
due to defect in the gene expression of glucokinase ( glycoltic enzyme) (126), insulin 
promoting factor-1(IPF-1) ( involve in embryonic development of pancreatic islets) and  
hepatic nuclear factors such as hepatocyte nuclear factor- 4α (HNF-4α), hepatocyte 
nuclear factor -1α ( HNF-1α), hepatocyte nuclear factor-1β (HNF-1β ) (126) which are 
disseminated on the pancreatic beta cells and engage in carbohydrate metabolism by 
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controlling glucose transporters and enzymes concerned with glucose metabolism
(122).Thus mutations in these genes result in the inefficiency of the beta cells of the 
pancreas to secrete sufficient insulin (122). Because of its prevalence in diverse forms 
such as MODY 1, MODY 2, MODY 3, MODY 4, MODY 5, MODY, it is considered 
heterogenic (125). Other monogenic forms of type 2 diabetes include mutation in 
mitochondrial tRNA leu  which can cause  maternally inherited type 2 diabetes (127) and 
mitochondrial syndrome (myopathy, encephalopathy, lactic acidosis, and stroke) ( 
MELAS)  (128).
As there are many factors involve in the progression of type 2 diabetes such as 
obesity, insulin sensitivity, and beta cell function, therefore, the genetic constituent of 
type 2 diabetes is multifarious rather than homogenous. Studies demonstrated that 
mutations in multiple genes that adjust insulin secretion, action, and insulin signaling add
more to the advancement of type 2 diabetes rather than single gene mutations (122). 
Nearly 200 candidate genes were identified by candidate gene approach which 
investigates the connection between a particular gene that involve in the regulation of 
insulin secretion, carbohydrate and fat metabolism and type 2 diabetes. But, their 
predisposition to type 2 diabetes is very small. Candidate gene approach was 
unsuccessful to recognize the genes that are more vulnerable to progression of type 2 
diabetes (122). Further research with large sample sizes are needed to explore the genetic 
contribution of type 2 diabetes in general as well as in ethnic populations. Hence, 
research with a novel tool “genome wide scans” is lending a hand to the researchers to 
identify the genes that are more liable to common forms of type 2 diabetes. 
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Diet and diabetes
In the US, obesity is the predisposing factor for type 2 diabetes and is 
disproportionately affecting women, minority ethnic groups such as Native Americans 
(129-131), African Americans (132), and children with less than high school education 
(133). Though most of the Americans are health conscious and aware of diet-related 
disorders like overweight and obesity-induced diabetes, they continue to gain weight. The 
proportions of overweight individuals gradually have increased from 24.3% in 1960 to 
33.3% in 1991 (134, 135). Although there is a large body of evidence that overweight is a 
risk factor leading to diabetes (73-80) unfortunately the US population is becoming more 
obese as time passes. Aside from excess caloric intake and reduced physical activity,
numerous other factors influence the prevalence of diabetes and obesity (136, 137). These 
factors include low intake of dietary fiber (138), increased consumption of refined 
carbohydrate (137), and inadequate consumption of fruits and vegetables (139, 140). 
Although there has been a consistent decline in the intake of dietary fat from 40% to 33% 
in recent decades in the US, this level remains to be higher than the recommended daily 
allowance of (30%).  Nearly, 58 million Americans are affected with obesity and its 
related disorders due to high fat diet (135, 141). It has been found that for addition of 
every one kg of weight above the ideal body weight, the risk of diabetes increases by 
4.5% (1).  During the past several decades, fast food has played a major role in the 
American diet. It is defined as the “food purchased in self service or carryout eating 
places without wait service”. Fast foods are rich in calories, proteins, carbohydrates, 
saturated fats, total fat, and cholesterol and are usually low in fiber, calcium and vitamins 
such as A, and C. French fries, hamburgers are the rich income sources for fast food out 
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let owners (142). According to a survey by USDA , 56% of US adults eat away from 
home and out of these 33% go to the fast food restaurants  and fast food accounted for 
14% of the total energy intake in the year 1995 (142). It was reported that women are the 
frequent eaters in fast food outlets and a direct relation existed between total energy and 
fat intake (142).French et al.(2000) investigated the  relationships between demographic, 
behavioral and dietary factors and the frequency of using fast food restaurants in a 
community based sample of 891 adult women aged 20-45. The results showed that the 
frequency of using fast food restaurants was considerably higher in young women, in 
individuals with low income, particularly among the ethnic groups, and people with
greater body weight. High consumption of fast foods is directly associated with excess 
weight gain and obesity. Thus fast food plays a dominant role in the excess accumulation 
of calories in the body predisposing to obesity and diabetes (143). 
The findings of a number of epidemiological studies (37, 2, 40) suggest that the 
prevalence of DM in the US is greater among the minority ethnic populations than 
Caucasians. Adaptation of western life-style has resulted in an increase in the prevalence 
of type 2 diabetes in ethnic groups as evident by migration of ethnic groups to the US 
which has resulted in change in the composition of traditional diet (132). Environmental 
factors such as excess accessibility to food, low cost of fast foods, change in the 
composition of conventional diet style, sedentary life, and television advertisements of 
fast foods all can be considered contributing factors to obesity and thereby leading to 
diabetes especially in ethnic groups (132, 140, 144).By projecting the available 
immigration data, 50% of the US population would be Hispanics and Asian origin by the 
year 2030. Therefore, the prevalence of type 2 diabetes would reach its maximum in US, 
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provided the influence of western life style continues on these populations (1). Several 
(132, 140, 144) studies on many ethnic groups like Native Americans, African Americans 
(145), Hispanic Americans (146), Pima Indians (38) , have reported that excess caloric 
intake and physical inactivity contribute to type 2 diabetes in US. Hence, westernization, 
migration, and acculturation all play a significant role in changing traditional dietary 
habits and contribute to high intake of fat, calories, predisposing to DM and obesity.
Physical inactivity and diabetes
Epidemiological evidence suggests that physical inactivity is one of the 
important determinants for the higher prevalence of type 2 diabetes among the minority 
ethnic groups such as Native Americans (144), Asian Indians (147), Chinese (148), 
Creoles (149), Polynesians (150), Micronesians (151), and Melanesians (152). Physical 
inactivity is a predisposing factor to obesity (153-155) and according to many 
longitudinal and cross sectional studies obesity is determined as a primary contributing 
factor to NIDDM among Native Americans, Asian Indians, Chinese, Creoles, 
Polynesians, Micronesians and Melanesians (144, 147-152). Therefore, in brief, “obesity
associated with physical inactivity is the primary risk factor in the causation with type 2 
diabetes mellitus”.
Insulin resistance (IR) is the characteristic feature of type 2 diabetic patients 
(156). Studies have demonstrated that obesity (Visceral obesity) (157), sedentary life 
style, lack of physical fitness (158) can aggravate IGT and insulin resistance. Therefore, 
studies advocate” physical activity” as one of the effective strategies to prevent 
underlying risk factors such as obesity, reducing the risk of developing diabetes (159-
161). 
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It is well known that exercise can improve insulin sensitivity (162, 163) in type 2 
diabetics and reduce the incidence of mortality in both men and women from ischemic 
heart diseases (164). Exercise enhances the utilization of glucose by muscles and reduces 
hyperglycemia in IGT individuals suffering from type 2 diabetis. It also stimulates the 
release of catabolic hormones such as glucagons and catecholamine that inhibit insulin
action and improve insulin sensitivity and lipid metabolism (164, 165). Many studies 
have documented the existence of significant inverse relation between the amount of 
exercise and disorders such as type 2 diabetes (159), obesity (154), hypertension (166)
(167), hyperlipidemia (168) and ischemic heart disease (169). Epidemiological studies 
have also recognized similar phenomenon between diabetes and physical inactivity 
among Mexican Americans (170), blacks (171), Pima Indians (172) , Asian Americans
(173). However, interestingly the inverse association predicted between physical activity 
and occurrence of diabetes was found to be higher in Mexican and black men and 
surprisingly not in these two ethnic groups of women (170, 174). On the contrary, 
another study by Harris and colleagues (175) did not reveal such variations between men 
and women. It was also found that white women were more physically active than Native 
American, Hispanic, black women (176).
 In addition to exercise, weight reduction would be an effective measure in 
reducing the risk diabetes and obesity (177, 178). According to the present weight 
management program, increased physical activity and reduced caloric intake by about 
500 to1000 cal/day will produce a weight loss of 0.6 kg (1.5 lb) per week, and 7 to10% 
reductions in body weight over 6 to12 month period (65). Intervention trials have 
demonstrated that reduced intake of calories and increased physical activity produce a 
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negative energy balance which in turn reduces the risk of developing type 2 diabetes 
(179, 180). The Finnish Diabetes Prevention Study (181) documented that effective 
individual counseling resulted in 58% reduction in the risk of type 2 diabetes in subjects 
who received high fiber/low fat diet along with exercise. This supports the hypothesis 
that life style modifications are directly related to the incidence of type 2 diabetes (181).
Diabetic Prevention Program Research Group (182) also demonstrated a 58% 
reduction in the incidence of diabetes in impaired glucose tolerance individuals with body 
mass index (BMI) of 34.0 who were assigned a lifestyle modification program when 
compared with the group assigned metformin and placebo. Also, a meta analysis of 
controlled clinical trials proposed an inverse relation between exercise and blood levels 
of glycated hemoglobin (Hb A1c) (a predictor of type 2 diabetes (183).
As type 2 diabetes is a lifestyle-related disease, current guide lines (184) advocate 
the incorporation of regular and physical activity combined with weight loss to improve 
the metabolic syndrome variables such as insulin sensitivity, insulin resistance, glucose 
tolerance, and lipid profile that contribute to the causation of type 2 diabetes.
Prevention and Treatment of Diabetes in Postmenopausal Women
Lifestyle modification and diabetes
Life style modification plays a significant role in the prevention and treatment of 
type 2 diabetes and its related complications (185). A change in life style includes weight 
reduction, physical exercise, and calorie reduction (186).
Obesity is one of the major risk factors for the development of type 2 diabetes 
(73). A strong correlation exists between obesity and diabetes in both the sexes (187). In 
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obese individuals, the occurrence of type 2 diabetes is 3-7 folds higher (188, 74). Body 
mass index is a strong indicator of obesity and potential determinant of the development 
of diabetes. Progression of type 2 diabetes increases 20-fold in adults whose BMI is 
greater than 35 kg/m2 (188, 74). The rationale of this statement is to highlight the 
importance of weight reduction, a life style modification in the prevention and treatment 
of type 2 diabetes. Many studies (189-192) have been carried out to investigate the 
beneficial effects of weight loss in individuals with type 2 diabetes and insulin resistance. 
Weight loss have been shown to improve glycemic control, insulin action, reduce serum 
levels of fasting glucose (189, 190), total cholesterol, triglyceride, low-density lipid 
protein (191, 192) in patients with type 2 diabetes. Therefore, weight reduction is 
considered to be the main strategy for overweight, obese individuals and diabetics as 
well. Weight loss can be achieved through reduced caloric intake and increased physical 
activity.
Reduction in total caloric intake is an important component in the treatment of 
obesity and diabetes. According to National Heart, Lung, Blood Institute (NHLBI) 
(193)and Obesity Education Initiative Expert Panel (OEI) (194), a diet that supplies
1000-1200 K Cal/day for women and 1200 to1600 Kcal/day for men provides an energy 
deficit of 500-1000 Kcal /day and is considered low calorie diet. Low fat diet 
recommendation is a common remedy for both overweight and obese individuals. The 
findings of short-term intervention trials (195, 196) and randomized controlled trails
(197, 198) suggest that fat restricted diet (25-30% of calories) results in decreased energy 
intake with subsequent weight loss.  However, the long-term effect of fat restricted diet 
on weight loss is unclear and the evidence is insufficient. Aside from high fat diet, 
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excessive intake of carbohydrate aggravates dyslipidemia, which is often associated with 
insulin resistance in type 2 diabetes (199). Although there are studies (200-205) that have 
demonstrated the efficacy of low carbohydrate (CHO) and high protein/high fat diet in 
reducing body weight in short-term basis, the long-term efficacy and safety of these types 
of dietary approaches are questionable. One possible explanation for the beneficial effects 
of low carbohydrate may be unrelated to the amount of carbohydrate consumed, rather 
has to do with the type of carbohydrate (198). For instance, a study by Heilbronn LK and 
colleagues (199) has shown that adults who have consumed low glycemic index foods 
have experienced weight loss. Therefore, this and similar questions are needed to be 
answered in well-designed clinical trials. 
To date based on the existing body of information; it is improbable to conclude 
that one particular diet is appropriate for all overweight, obese/diabetic individuals. 
Dietary recommendations should be based on a number of factors including individual’s 
individual food preferences, circumstances, cultural ethnic preferences and his/her motive
towards weight management should be taken in to consideration (206). Multiple 
approaches are available for an efficient management of energy intake and weight loss. 
For instance, fat and carbohydrate restricted diets will reduce the caloric intake (207)
(199), diets rich in fiber, whole grains and fruits will increase the volume of food and 
improve satiety (208)
The current dietary guidelines of the American Diabetes Association (209), the 
American Heart Association (210) , and the National Cholesterol Education Program 
(NCEP)–Adult Treatment Panel (ATP III) (193), include a diet rich in vegetables, whole 
grains, low fat or non fat dairy products, fish, legumes, poultry, lean meats and limit the 
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intake of saturated fat, trans fatty acids, cholesterol, salt intake of 6 grams or less per day
and alcohol intake (no more than 2 drinks per day for men and one drink for women). 
One drink equals to 12 oz of beer, 5 oz of wine or 1.5 oz of distilled spirits. Each drink 
contains 15 g of alcohol. Additionally, weight loss should be gradual with following 
moderate and practical dietary recommendations, e.g. reduction in total caloric intake, 
approximately 500-1000 kcal on a daily basis while receiving a well balanced diet in 
terms of macro- and micro-nutrients. These dietary guidelines are based on the risk 
factors for coronary heart disease (CHD), which is an important consideration for 
individuals with type 2 diabetes; because the risk of developing CHD is 3 to 7 fold higher 
in type 2 diabetics than non-diabetic individuals (193).  
Apart from diet restriction, exercise also plays an important role achieving ideal 
body weight. Many epidemiological studies (211, 162, 212), have provided evidence that 
physical inactivity can lead to type 2 diabetes and suggested that regular physical activity 
improves insulin sensitivity, glycemic control (163) and delays the development of type 2
diabetes, and reduces the overall mortality rate as a consequence of DM (164). It has 
been shown that 30-minute moderate intensity exercise on a daily basis lower the risk of 
metabolic syndrome (213). Hence, diet therapy together with exercise can act 
synergistically to reduce the incidence of type 2 diabetes. Nonetheless, it is essential for 
the individuals with type 2 diabetes with or without other associated risks to receive 
professional advice before initiating exercise (206). To sum up, strict adherence to diet 
restriction and moderate intensity exercise will help in the efficient management of 
diabetes and cardiovascular diseases and their underlying risk factors. 
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Antidiabetic drugs and diabetes
Diet restriction, modest exercise, lifestyle intervention sometimes fails to control 
blood sugar and do not enhance the production of endogenous insulin and responsiveness 
of a specific tissue to insulin. Hence, pharmacotherapy is effective, if calorie restriction 
and physical activity proves to be ineffective (17).
The drugs used in the management of diabetes are categorized into insulin augmenting 
agents and insulin assisting agents (214). Insulin augmenting agents include sulfonyl 
ureas (glimepride, tolbutamide) and meglitinides (repaglinide) (214). Sulfonylurea 
derivatives bind to the receptors on the β-cells and close the potassium channels that will 
instigate the production of endogenous insulin and inhibit β-cell apoptosis (214). There 
are long–acting sulfonylurea ureas (glimepiride) (215) and short–acting: sulfionyl ureas 
(tolbutamid) (216). The treatment effects of these drugs depend on the site and duration 
of their actions.
These drugs are contraindicated when there is severe hypoglycemia due to 
inefficient renal clearance, renal impairment, hepatic dysfunction and cardiac failure (19, 
217). A recent retrospective cohort study reported by Bell DS and colleagues (2 18)
reported that sulfonyl monotherapy exposure resulted in heart failure. On the other hand, 
there is conflicting evidence by a UK prospective diabetes study (219, 220),  that micro-
and macro-vascular complications were noticed to be diminished with sulfonylurea 
derivative treatments. Maru et al  (2005) (221) reported that the risks of heart failure exist 
due to any kind of antidiabetic drugs within the first year of diagnosis. It has also been 
suggested that, the risk of heart failure depends not only on the therapy itsself but also on 
the severity of the disease and duration of the preclinical condition and the need for drug 
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therapy (221). Biguanide (metformin), a –glucosidase inhibitors (acarbose), and insulin 
sensitizers like thiazolidinediones ( rosiglitazone) are another group of drugs that come 
under insulin assisting agents (222). Each drug has specific site of action and specific 
function in the control of hyperglycemia. 
Thiazolidinediones mainly act on the adipose tissue. These drugs activate 
proliferator–activated receptor gamma expression (transcription factor) (PPAR γ).  
Activation of (PPAR γ) regulates the relocation of triglyceride deposits in visceral and 
subcutaneous depots and reduces the circulation of non-esterified free fatty acids 
(NEFFA) and glycerol. This will prevent excess accumulation of fat in hepatic adipocytes 
and intramyocytes and alleviate hepatic and skeletal muscle insulin resistance (223)
(224). Thiazolidinediones also play a vital anti-inflammatory role by reducing the 
production of proinflammatory cytokines such as tumor necrosis factor -α TNF α and 
interleukin 6. It also increases the concentration of adenopectin, an adipokine that in turn
inhibits hepatic gluconeogenisis, reduces plasma glucose and stimulates lipid oxidation 
and glucose uptake by skeletal muscles (225).
Beguanides (Metformin) acts on the liver and prevents fasting hypoglycemia by 
decreasing hepatic glucose output (226). Treatment with this drug prevents weight gain, 
which is a common feature in type 2 diabetics (222). Glucosidase inhibitors such as 
Acarbose increase the volume of the food by absorbing moisture and reduce satiety. They 
also delay digestion and absorption of complex carbohydrates and prevent hyperglycemia 
(227). Sometimes, oral anti-diabetic drugs can be ineffective in severe hyperglycemic 
conditions and the need for exogenous insulin may be necessary. Hence, insulin alone or 
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combined therapy with oral anti-diabetic drugs is prescribed depending on the severity of 
the condition (18).
Although anti-diabetic drugs exert many beneficial effects in control of 
hyperglycemia, the prolonged use of these drugs can produce adverse effects such as 
severe hypogyglycemia (228), weight gain (229), lactic acidosis (230), flatulence with 
sufonyl urea, thiazolianediones , biguanides , glucosidase inhibitors (231). Therefore, the 
use of complimentary and alternative medicine (CAM) and the incorporation of natural 
supplements in the diet to prevent  diseases such as Diabetes, cardiovascular diseases, 
osteoporosis, cancer are becoming more prevalent (232). Currently, there are numerous 
studies being conducted to investigate the health benefits of bioactive-rich food sources 
such as flaxseed and soy on hyperlipidemia, hyperglycemia and other chronic diseases.
Role of Bioactive Food Components in Preventing Chronic Diseases
Phytoestrogens
Phytoestrogens are naturally occurring plant compounds, which either exerts 
estrogenic and antiestrogenic activity depending on specific tissue or estrogen level (21)
(22). These compounds are heterocyclic phenols and exhibit structural similarities to 
estrogens. They are classified in to three main groups – isoflavones, coumestans and 
lignans . Genestin and diadzein are the bioactive isoflavones while biochanin A and 
formononetin are the precursors for these isoflavones. Lignans are widely present in the 
plant kingdom and helps in lignin formation in plant cell walls. Secoisolariciresinol and 
matairesinol are the precursors for enterolactone and enterodiol. Coumestrol and 4’-
methoxy coumesterol are biosynthetically similar to isoflavones. Legumes, seeds and 
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whole grains are the rich sources of phytoestrogens (21, 22). Soybeans and soybean 
products are abundant sources of isoflavones (233). Chickpeas, legumes, cloverleaves, 
toothemelic and blue grass are also good sources of isoflavones (234). Coumestans are 
found in alfalfa and sprouts of clover, split peas, kala chana seeds, pinto beans, lima 
beans, and soybean sprouts also contain small amounts of coumestrol . Plant foods such 
as flaxseed, oil seeds are rich in lignans (234).
Phyoestrogens exist in plants as glycosides. Once ingested, glycosides undergo 
hydrolysis and subjected to fermentation by intestinal bacterial beta- glucosidases and 
converted in to bioactive aglycones (23). In the distal part of the intestine, specific 
metabolities are formed. These uncongugated specific metabolites (aglycones) are 
absorbed in the intestinal tract and reach the liver to form glucoronides, which are then 
either re -excreted through bile and urine or enter enterohepatic circulation (23). The
production of specific metabolites varies depending on gastrointestinal flora, antibiotic 
use and diet (235). The Biological effect of phytoestrogens depends on the time of 
exposure. For example, in premenopausal women, the intake of phytoestrogens may 
produce adverse effects such as increased risk of breast cancer. This is due to the 
presence of natural estrogen and intake of estrogen rich diet. For normal postmenopausal 
women, because of lack of production of natural estrogen, estrogen rich diets have 
beneficial effects in relieving postmenopausal symptoms, breast cancer, cardiovascular 
diseases (CVD) (22).
The type of food consumed, the level of intake and the specificity of the 
compound in the diet influence the biological activity of phytoestyrogens (236, 237). The 
diet of an individual varies depending on the geographical area. For instance, western diet 
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is different from the Asian diet (238). Therefore, the incidence of breast (239, 240), 
ovarian cancers (241), prostate carcinomas (242), CVD (243) is less in Asian population 
compared to westerners. This might be due to the intake of phytoestrogen-rich diet by 
Asians. Lately, due to change of life style and dietary habits because of westernization in 
Asian countries, the risk of cancers (239-242), cardiovascular diseases (243), and similar 
chronic diseases are towards the rise. 
A number of beneficial effects are associated with the intake of phytoestrogens, 
with regard to postmenopausal symptoms such as hot flashes. In Asian women the 
incidence of hot flashes are lower than the Caucasian women (244). Phytoestrogens have 
also been reported to protect loss of bone mass in pre- (245) and post-menopausal (246)
women. Studies have reported that the intake of soy protein in overectomised rat 
prevented bone loss as indicated by an increase in bone formation markers (e.g. serum 
alkaline phosphotase, and osteocalcin levels) compared with the control animals (247, 
248).
A number of studies (249 -252) support the hypothesis that adequate intake of 
isoflavones and lignans reduce the risk of cancer. Epidemiological data have shown that 
soy consumption reduces the risk of prostate cancer in Japanese men (253). Similarly, 
several studies have established a negative association between consumption of soy/soy 
protein and the development of lung cancer (254), stomach cancer (255), breast cancer 
(256) and rectal cancer (257).
It has also been shown that phytoestrogens exert beneficial effects in 
postmenopausal women by improving lipid profile and reducing the risk of developing 
CVD (258). Many studies (259, 260) support this notion by showing the positive effect of 
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intake of soy protein on the total cholesterol and low-density lipoprotein concentrations 
in humans. Further, meta analysis of 38 controlled clinical trials also reported that intake 
of soy protein decreased blood cholesterol, LDL and triglyceride concentrations (TGL) 
(261).
Phytoestrogens exert either estrogenic or antiestrogenic effect on a variety of 
tissues depending upon the availability of ER-alpha and ER–beta receptors through the 
classical genomic effects (24, 25). However, the affinity of phytoestrogens to binding to 
ER-beta receptors is far greater than those of ER- alpha (262). ER-beta receptors are 
more expressed in tissues such as bone, breast, cardiovascular system (263) and hence, 
phytoestrogens may show greater beneficial effects in preventing breast cancer, 
osteoporosis, CVD diseases in postmenopausal women  in the absence of substantial 
level of circulating estrogen.
Thus phytoestrogen influences different tissues depending on the length of the 
exposure, dose, and metabolites (264). The field as a whole is relatively new and further 
studies are underway to shed light on numerous health benefits of phytoestorgens,
Lignans
Lignans are a class of phytoestrogens that are found in seeds, whole grains, legumes and 
vegetables. However, among edible plant foods, flaxseed is the richest sources of lignans 
(265). Secoisolariresinol and matairesinol are the major components of plant lignans. 
These are the precursors for the production of mammalian lignans namely enterodiol and 
enterolactone (266). These precursors undergo hydrolysis, dehydroxylation and 
demethylation in the gut to form mammalian lignans (267). Plant lignans are absorbed 
31
and utilized in the small intestine by a series of deconjugation and conjugation reactions. 
Following the absorption process, hepatic phase II enzymes (UDP-glucoronosyl 
transferates and sulphotransferases) involve in conjugation of lignans with glucoronic 
acid and sulphate to form conjugates. These conjugates either enter enterohepatic 
circulation or get excreted through urine or bile-like natural estrogens (268). Later, the 
intestinal bacteria for further re- absorption, and metabolism of metabolites, deconjugate 
the conjugated lignans in the intestine. Thus, intestine serves as the primary site for 
biotransformation of plant lignans to mammalian lignans (268). It is well documented 
that biotransformation is affected in patients with ileostomies, because of the decrease in 
the enzymatic and fermentative capacity of the intestine (269). Determinants such as 
quantity and quality of the lignans, (270), and presence of constipation will hasten the 
process of biotransformation (271, 272) whereas increase in body mass index, smoking
(271, 272), high fat diet (273), will lower biotransformation process. Thus, the levels of 
enterolactone in blood and urine are influenced by a number of variables which may 
cause the findings of one study to be different from another study.  
A close association has also been observed between enterolactone concentrations 
in blood and hormone-related diseases such as osteoporosis (274), cancer of breast (275)
and prostate (276). This has lead researches to investigate the process of absorption and 
biotransformation of lignans and their influence on the hormone-related diseases.The 
hormone-like compounds, enterolactone and enterodiol, are found to be weakly 
estrogenic and therefore being able to influence the production, metabolism and activity 
of biological estrogen and cell proliferation, differentiation, adhesion and angiogenesis, 
thereby acting as natural anti-carcinogens (270).
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Many human (278, 279) and animal studies (281, 289) have depicted that intake of 
lignan-rich foods reduce the risk of developing breast, and prostate cancers. Classical and 
nested case control studies have examined urinary, serum and plasma enterolactone as 
biomarkers of lignan intake and have found that the higher the concentration of 
enterolactone in blood and urine, can be interpreted as lower risk of acquiring breast 
cancer in  pre- and post-menopausal women and in patients with breast cancer (27, 272, 
277). A study by Serraino and Thompson (278) also revealed a significant reduction in 
epithelial cell proliferation by 38.8 - 55.4% and nuclear aberrations by 58.8 - 65.9% in 
mammary gland of female rats fed with lignan-rich flaxseed flour or defatted flaxseed 
meal (5% or 10%) and the effect was significant at 5% level of flaxseed flour/defatted 
flaxseed meal.
Thus, dose dependent studies have provided significant insight as how lignans 
prevent various types of cancers.  
Much evidence has accumulated in support of protective effect of lignans against 
the risk of prostrate cancer in men. In a study by Mills et al. (1989) (279), high intake of 
beans and lentils, rich sources of lignans, and dried fruits resulted in decreased risk of 
prostate cancer in men. Animal studies including those of rats and mice also have 
exhibited similar results (280, 281). In the studies, for instance, when animals were fed 
with high rye bran diet (a good source of lignans), they experienced apoptosis of prostate 
tumor cells. 
Overall, it can be assumed that, not only the estrogenic/antiestrogenic properties 
of lignans (282), but also the antioxidant (283, 284) properties  have some protective 
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effect against diseases associated with free radicals such as cancer, cardiovascular disease 
and diabetes (282).
Flaxseed
Flax (Linum usitatissimum) is a blue flowering crop that was identified in Near 
East some 10000 years ago (285). Presently, researchers are focusing on the health 
benefits of flaxseed components such as lignans, omega 3 fatty acids and soluble fiber. 
Whole flaxseed contains approximately 41% fat, 28% dietary fiber, and 21% protein. It 
also contains minerals and vitamins in considerable quantities. Flax contains an average 
of 35% of its mass as oil and is a rich source of omega 3 fatty acids (alfa linolenic acid) 
(286).
Until now, most of the research on flaxseeds has focused on its estrogenic and 
antioxidant characteristics, the former having influence on hormone related diseases like
cancer of breast, prostate and colon, and the latter showing considerable effect on free 
radical-associated diseases of cardiovascular system, diabetes and inflammatory diseases. 
Animal and cell culture studies have shown that dietary flaxseed and its 
components reduce the growth and metastasis of established estrogen receptor negative 
(ER-ve) human breast cancer cells in nude mice (287). Flaxseed has also been shown to 
inhibit the growth of tumor cells in the human colon by anti estrogenic property (288), 
decreases the number of aberrant crypt cell foci proliferation, and increase apoptotic 
index in the distal colon of male rats with colon carcinogensis (289) and prostatic 
carcinoma in transgenic mice (289). Similarly, flaxseed has been shown to be effective in 
inhibiting the growth of melanoma cells and tumors in the lungs of C57BL/6 mice (290).
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Additionally, several human studies (291, 292) have confirmed the 
anticarcinogenic effects of flaxseed and its components. For instance, in a study by 
Thompson et al. (291) showed that consumption of 25g flaxseed daily for 39 days 
reduced tumor cell proliferation, and increased apoptosis of breast cancer cells in 
postmenopausal patients with recently diagnosed breast cancer. A similar finding was 
reported among clients with prostate cancer who were put on 30 grams of flaxseed/day 
with low fat meal (20% of Kcal or less) (293). In that study, the biomarkers of prostate 
neoplasma (eg: prostate specific antigen, testosterone, free androgens) have shown a 
decline. The results suggested that fat restriction and flaxseed supplementation decreased 
epithelial cell proliferation and its associated biomarkers. 
Further, much evidence has accumulated on the effect of flaxseed on the levels of 
lipid parameters and biomarkers of cardiovascular diseases. A randomized clinical trial 
by Dodin et al.(2005) (294) found that consumption of 40 grams of flaxseed/day by
French Canadian postmenopausal women (n=101) for 12 months reduced serum total and 
high density lipoprotein cholesterol concentrations compared to those who were put on 
wheat germ placebo (n=98). Another study by Nestel et al (295)established a remarkable 
association between intakes of 29 grams of alpha linolenic acid from margarine products 
based-on flaxseed and arterial compliance, an important index of circulatory system. The 
findings of that study (295) suggested that there was a significant improvement in arterial 
compliance in obese subjects, regardless of raise in LDL oxidizability and diminished 
insulin sensitivity.
Prasad et al.(1999) (286) established the potential effect of flaxseed as antioxidant 
and its role in the prevention of hypercholesterolemic atherosclerosis, a condition that 
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occurs due to over production of free radicals resulting from stimulation of 
polymorphonuclear leucocytes by hypercholesterolemic condition. Their findings 
demonstrated that secoisolariciresinol diglucoside (SDG) reduced total cholesterol by 
33%, LDL-C by 33% and there was a significant increase in HDL-cholesterol of greater 
than 140% in rabbits. Furthermore, there were considerable decreases in 
malondialdehyde chemiluminescence (lipid peroxidation product) and perceptible 
increase in antioxidant reserve in rabbits fed with 1% cholesterol + 15 mg of SDG/kg 
body weight compared to control group. Thus, oxidative stress plays a major role in the 
pathogenesis of cardiovascular disease.
Several lines of evidence indicate that oxidative stress is one of the underlying 
factors of diabetes. Increase in plasma free radical concentration increases fasting plasma
insulin in type 2 diabetic patients (296). It has also been reported that increased levels of 
reactive oxygen species (ROS) impairs glucose tolerance, decreases insulin sensitivity 
and increases insulin resistance in patients with type 2 diabetes (297). Increased levels of 
ROS  adversely affect the function of islet cells of pancreas and hampers glucose 
absorption resulting in hyperglycemia.  The concentration of malondialdehyde increases 
and alters cell impermeability and cell apoptosis (297).
Based on this concept and the potential antioxidant activity of SDG, Prasad et al. 
(2000) (2001)(298, 299) conducted a study evaluating the ability of SDG in preventing 
type 1 and type 2 diabetes. His findings indicated a positive association between 
oxidative stress and non insulin-dependent diabetes (NIDDM) and insulin-dependent 
diabetes (IDDM). Treatment with SDG prevented NIDDM in female Zuncker rat model 
of type 2 diabetes and IDDM in diabetic prone Biobreeding rats (Bbdprats).
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The studies in which the effects of flaxseed or its bioactive components have been 
investigated in relation to diabetes are sparse. Further research is needed using human 
volunteers and animal models to confirm the beneficial effects of intake flaxseed and its 
lignans on glucose metabolism. Thus the present research mainly focused on how 
hormone deficiency hampers glucose metabolism and investigated the extent to which 
flaxseed consumption improved fasting blood glucose levels in Native American 
postmenopausal women. Future clinical trials are needed to investigate the role of 





A total of fifty-five mild to moderate hyperglycemic fasting blood glucose (FBS) > 110 
mg/dL but less than 126 mg/dL) and hypercholesterolemic (total cholesterol level >200
but less than 380 mg/dL) Native American postmenopausal women with mean age 47 to 
63 years of age who were not on hormone replacement therapy (HRT), for at least six 
months prior to study, were enrolled for this study. The study protocol was approved by 
the Institutional Review Board (IRB) at Oklahoma State University. Volunteers were 
accepted into the study by meeting the following criteria: being postmenopausal as 
determined by at least 1 year of amenorrhea, FBS levels of more than 110 mg/dL but less 
than 126 mg/dL, not taking any medications known to alter carbohydrate and lipid 
metabolism, no history of hypo- and hyperthyroidism, liver or kidney diseases. Potential 
candidates were recruited from health fairs conducted by Native American tribes and 
advertisement at large. Participants were provided with a verbal and written explanation 
of the study. They were assured that their participation in the study was completely 
voluntary and their information would be kept confidential. After signing the consent 
form approved by the IRB, detailed medical and diet histories were obtained.
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Experimental design
The experimental design was a randomized controlled design. Eligible subjects were 
randomly assigned to one of the following three treatment groups (n=18 per treatment 
group): 1) control; 2) flaxseed; and 3) flaxseed+additional fiber for a period of 3 months. 
Approximately, thirty grams of flaxseed was provided to each of the subjects in the 
flaxseed and flaxseed + fiber groups in the form of bread, muffins, and powder as part of 
their daily diet. The baked products were stored at -20o C prior to distribution to subjects. 
They were provided to the subjects frozen and subjects were instructed to keep them 
frozen until ready for consumption. Subjects thawed the products overnight in the 
refrigerator or defrosted them in a microwave oven for an immediate consumption. The 
treatment regimens were distributed to subjects on a biweekly basis. The participants in 
the flaxseed and flaxseed+fiber treatment groups were asked to consume 2 muffins (~10 
g of flax), 2 slices of bread (~3 g of flax) and 2 tablespoon of flax powder (~16 g) per 
day, whereas the participants in control group consumed 2 oat muffins and 2 slices of  
bread  per day. Additional ~ 8g dietary fiber was added to the flaxseed+fiber treatment 
group. The flaxseed+fiber treatment regimen was included to determine if the 
combination of these two components will have synergistic or additive effect in 
improving glucose profile compared to flaxseed alone. The treatment regimens provided 
similar amounts of calories, and protein. Participants were advised to adjust their daily 
food intake in order to maintain their caloric intake. Composition of the study products is 
presented in Table 1.
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Dietary assessment and anthropometric measurement
Height, weight, hip and waist circumferences were measured and the waist to hip 
ratio was calculated at baseline and at the end of the study. The total body fat, and lean 
mass content was measured using bioelectric impedance (Biodynamic Model 310e, 
Biodynamics Corp., Seattle) which measures the impedance to the electric current 
through the body. Higher impedance means greater body fat content. With the exception
of height, all other measurements were repeated at monthly visits. If weight gain was 
observed during the course of the study, the participants were counseled regarding their 
daily food intake and were advised to make simple adjustments in their daily caloric 
intakes.
To ensure compliance, the following steps were taken 1) a monthly calendar was 
given to the participants to record their intake of regimens daily; 2) participants were 
asked to return unused dietary regimens and were given new supplies and a new calendar 
during their monthly visits; 3) a bi-monthly 24 hr food recall over the phone was done on 
a random basis to check for compliance; 4) after three months of treatment blood draw, 
anthropometric measurements, physical activity and dietary assessment were repeated. 
An additional 7-day physical activity questionnaire enquiring about the activities of the 
participants was also noted down.
Blood collection and processing
Fasting venous blood samples, approximately 20 mL, were obtained from each 
participant in ethylendiaminetetraacetic acid (EDTA) and non-EDTA vacutainer tubes at 
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the beginning and at the end of study. All blood samples were placed on ice until 
processing. Plasma and serum were separated by centrifuging the samples at 2500 g for
20 minutes at 4 oC. Serum and plasma were aliquoted and stored at -80 oC until 
analyses. At the end of the study all samples were run together to minimize variability.
Serum analyses
Fasting blood sugar and glycated hemoglobin from serum and whole blood were 
analyzed using ACE Clinical Analyzer (Monclair, NJ). The clinical analyzer was 
calibrated using Gemcal reference serum (Alfa Wassermann, Inc; West Caldwell, NJ) 
before each test. Alfa Wassermann quality control (QC)-1 and (QC-2) were used as 
control in all test.
In serum glucose reacts with ATP in the presence of hexokinase and magnesium. 
Hexokinase helps in catalyzing phosphorylation reaction and converts glucose to glucose 
-6-phosphate. In the presence of glucose-6-phosphate dehydrogenase and (NAD+), 
oxidation of glucose-6-phosphate to glucose-6-phosphogluconate and nicotinamide 
adenine dinucleotide (NADH) takes place. The NADH produced is absorbed at 340 nm 
which was measured bichromatically at 340 nm/378 nm is directly proportional to the 
initial amount of glucose.
Glycated hemoglobin in whole blood was estimated by the agglutination 
inhibition assay method. It determines the quantity of hemoglobin A1c (HbA1c) and total 
hemoglobin (THB) in whole blood. Hemoglobin A1c agglutinator agglutinates with 
hemoglobin A1c (HbA1c) antibody in deficiency of hemoglobin A1c (HbA1c ) in the whole 
blood. If the (HbA1c) concentration is more in the blood it competes with agglutinator to 
bind with the (HbA1c) antibody binding sites and inhibits agglutination of Hemoglobin 
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A1c agglutinator. The absorbance is monitored monochromatically at 592 nm and is 
indirectly proportional to the (HbA1c ) in the whole blood sample. Then (THB) is 
measured by alkaline hematin D-575 method. In this test, all the hemoglobinic 
derivatives are transformed in to alkaline hematin. A green colorsolution is produced and 
measured bichromatically at 573 nm and 692 nm. The concentration of the color 
produced is directly proportional to the (THB) concentration. Then percent hemoglobin is 
calculated by the following equation:  
HbA1c * 26.44/THB
Fasting serum insulin was analyzed by radioimmuneassay (RIA) method using 
human insulin-specific RIA kit from LINCO Research (St.Charles, MO). Human insulin-
specific RIA kit is used to quantitatively determine insulin in blood or serum by double 
antibody technique. In RIA procedure, a known concentration of a labeled antigen (125I-
labeled human insulin) is incubated with a constant diluted antiserum (Human Insulin 
Antiserum) with a purpose to limit the binding sites of antigen on the antibody. If an 
unlabelled antigen is added to the sample constantly, it competes with the labeled antigen 
to bind to the limited binding sites on the antibody. Therefore, there will be a decrease in 
binding of labeled antigen to the antibody binding sites as the concentration of unlabelled 
antibody increases. Thus, a standard curve is created with an increase in the 
concentrations of the standard unlabeled antigens. From this curve, the amount of 
unknown samples can be calculated. This method measures the true insulin levels.
Data management and statistical analysis
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All data obtained about the subjects were kept in lock cabinets with limited accessibility.
Upon completion of the study the data from laboratory analyses and questionnaires w ere 
entered into spreadsheets and double checked  for accuracy.
The experiment was a completely randomized design with repeated measures. 
Treatment is the main plot factor and was applied to each subject, while baseline andfinal 
values were considered the repeated measures. Results were expressed as mean ± SE.
The significance of percentage differences between and within treatments was assessed 
with Student's t test for paired data (two-tailed). Data were analyzed using PC SAS 
version 8.2 (SAS Inst., Cary, NC) using PROC GLM MIXED. The primary outcome 
variables were the change from baseline in fasting blood glucose, insulin and glycated 
hemoglobin values and homeostasis assessment model of insulin resistance (HOMA-IR.).
Analysis of variance technique was used to assess treatment (flaxseed vs. flaxseed with 
additional fiber vs. control) differences. Significant differences were determined using 





Out of the 55 participants recruited, 13 dropped out of the study. Nine women 
completed the control regimen, 17 completed the flaxseed regimen and 16 completed 
flaxseed + additional fiber regimen. One woman dropped out of flaxseed treatment group 
complaining of gastrointestinal discomfort. Subjects complaining of gastrointestinal 
problem and unpalatability of study food were given suggestions to incorporate the study 
food into their diet to reduce these problems. Four of the participants from the control 
group relocated and hence could not continue with the study. Eight subjects, 4 from 
control regimen, and 2 each from the flaxseed treatment groups did not give any reason 
for dropping out of the study. 
Nutrient intake
The baseline daily nutrient intake was determined using a food frequency 
questionnaire validated  by the National Institutes of Health (NIH). There were no 
differences in the baseline caloric intake as well as protein, carbohydrate, fiber, total fat, 
saturated fat, polyunsaturated fat and calcium intake (Table 2) among the groups. The 
nutrient intake of the subjects during the study was monitored by a 24-hr food recall 
conducted over the phone. There were no changes in caloric intake, carbohydrate and
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polyunsaturated fat consumptions among the groups while they were taking the study 
regimen (Table. 3). There was a tendency for an increase in protein (P=0.074) total fat 
(P=0.062), and saturated fat (P=0.099) intake in the flaxseed groups. Dietary fiber
(P=0.000) and calcium (P=0.015) intake were significantly increased in the flaxseed 
group.
Anthropometric measurements
The results of the anthropometric measurement are shown in Table 4. Age range 
for the study participants was 47-62 yrs. There were no significant changes in body 
weight after 3 months of consuming the dietary regimens. However, body weight of 
subjects in the control group tended (P=0.066) to decrease after 3 months of being on the 
study regimen.  The body mass index (BMI) did not change among the subjects in any of
the treatment groups but when compared to the baseline values there was a decrease in 
mean body weight of subjects in all three treatment groups. But, there was a significant 
difference in the mean waist circumference in the flaxseed group (P=0.01) but not in 
control and flaxseed+fiber group. The hip circumference was decreased significantly 
from baseline in the flaxseed group (P= 0.03), but the other groups showed no such a 
change. The percent body fat increased significantly among women in the flaxseed with 
additional fiber treatment group (P= 0.02).
Serum analyses
The glucose parameters are presented in Table 5. Consumption of 25-30 grams of 
flaxseed had no significant effects on blood glucose, insulin and HbA1 when baseline 
values were compared with their corresponding final values of the treatment groups. On 
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the average, women in the flaxseed + additional fiber experienced a 5% increase in final 
values of glucose compared to their baseline values (P=0.20). But there was a significant 
increase in the final fasting blood glucose values in control group (P = 0.0147). Also, 
insulin tended to increase in the control group but not in flaxseed groups. According to 
our homeostasis assessment model of insulin resistance HOMA-IR data, there were no 




The findings of the present study indicate that daily consumption of 
approximately 30 grams of whole ground flaxseed incorporated in to bread, muffins and 
energy drink did not show any change in  final values of the fasting blood glucose (FBS) , 
insulin  and glycated hemoglobin levels in Native American postmenopausal women. A 
significant increase in the FBS and insulin values were observed in the control group 
which were fed white bread and muffins. This finding shows that, although flaxseed and 
flaxseed + fiber treatment did not enhance the glycemic profile, still it has some treatment 
effect by maintaining the glycemic profile constant from baseline until the end of the 
study in the. Thus, it is reasonable to postulate that incorporation of flaxseed might 
improve hyperglycemia and hyperinsulinemia, if it is integrated in other foods rather than 
bread which in general has high glycemic index (308).
Since no study was conducted on the effect of flaxseed on glucose status in Native 
American postmenopausal women, it is difficult to compare the consistency of the results 
of our study with similar studies. However, the sustaining effect of flaxseed on glucose 
homeostasis to some extent agrees with the findings of an earlier study by Lemay et al 
(300) in which twenty five menopausal women were randomized to a crossover treatment 
with either 40 grams of crushed flaxseed, or 0.625 mg of conjugated equine estrogen or 
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combined with 100 mg of micronized progesterone daily for two months. The findings of 
that study (300) indicated that intake of 40 grams crushed flaxseed improved the glucose 
and insulin levels as successful as oral estrogen-progesterone administration. Intake of 
crushed flaxseed without incorporating it in bread and muffins, unlike in our study, might 
have significantly improve glucose profile of postmenopausal women who participated in 
the present study. 
In a study by Cunnane et al. 1993 (301) on six healthy volunteers (five males and 
two females) with average age of 30 ± 4 years were randomly assigned to 50 grams 
carbohydrate from either flaxseed or  wheat flour in the form of bread. After an over 
night fast, blood samples were collected and analyzed for every 15 minutes for one hour. 
The results showed that there was a 28% decrease in the incremental area under the blood 
glucose curve in the flaxseed group compared to the wheat regimen. Nonetheless, the 
study by Cunnane and colleagues (301) had a very small sample size of healthy human 
subjects and it makes difficult to draw firm conclusions from their findings. The 
bioavailability of sex hormones in addition to estrogenic properties of flaxseed might 
have added to the lowering effect of glucose levels in their study (302). In the earlier 
clinical trials, the amount of flaxseed used was approximately 40-50 grams. It was 
suggested that daily incorporation of 50 grams high α- linolenic acid flaxseed, produce 
encouraging effects in humans regarding glucose responses. However, according to the 
United States Food and Drug Administration (FDA) incorporation of 12 grams of 
flaxseed into 100 grams of food is generally recognized as safe (GRAS) (303). The FDA 
recommendation may a bit out of data and its recommendation is based on older varieties 
of flaxseed which contained much higher cynogenic compounds. More recent human data 
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suggest that inclusion of up to 50 grams of flaxseed can be considered safe and may 
enhance the glycemic profile of postmenopausal women, particularly the Native 
American postmenopausal women as is the case in the present study.  
There are also studies that are consistent with our findings (304, 305, 306). In a 
randomized cross over trial study by Juntunen KS and colleagues (304), twenty
postmenopausal women were assigned to rye bread, rich in lignans, (307) and wheat 
bread for 8 weeks with an 8-week washout period. No significant differences were 
observed in the baseline and final values of fasting plasma glucose and insulin which 
were the main measures of insulin-resistance in rye bread and wheat bread groups. 
Although, decrease in plasma insulin values were observed with rye bread period, but 
not significant (p=0.993).The effects of flaxseed and flaxseed + fiber effects in our study 
were similar to rye bread in sustaining  glycemic profile. On the other hand, there was a 
significant increase in the final values of fasting glucose (P=0.0147) in the control 
regimen group of our study which is in contrast to the findings of earlier studies by 
Jutntunen et al. (304) and Leinonen et al. (305). Therefore, collective review of literature 
advocates that, inclusion of foods with high glycemic index (308, 309, 310) in the daily 
diet may increase fasting blood glucose levels. Hence, the consumption of wheat bread 
may have added to the elevated fasting glucose levels in the control group in our study. 
Although, the types of bread seemed to have an effect on the fasting glucose values in 
the control group, there were no changes in the fasting glucose, glycated hemoglobin and 
insulin levels in the flaxseed and flaxseed +fibergroups. This suggests that there might be 
some treatment effects due to flaxseed and fiber in maintaining the glycemic profile. 
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In the present study, although, there was not a significant difference in the intake 
of protein (P=0.718) and fat (P=0.613) in all the three groups at baseline, an increased 
tendency in protein (P= 0.074) and total fat (P=0.062), saturated fat (P=0.09) intakes
were detected in flaxseed and flaxseed + fiber groups when assessed by 24-hr food recall
during the treatment period. Promising data put forward that both quantity and quality of 
protein (311) and fat (312) intake influence carbohydrate metabolism Protein intake 
stimulates the production of glucogenic substrates such as glutamine, alanine and lactate 
which undergo oxidation to produce glucose. Excess availability of amino acids alters the 
ratio of glucoregulatory hormones (glucagon and insulin) in diabetics. The glucagons 
response to amino acids will be high in diabetics and results in the hepatic 
gluconeogenesis and glycogenolysis and inhibits the ability of insulin to suppress the 
endogenous production of glucose contributing to hyperglycemia and stimulating the 
pancreatic beta cells to secrete more insulin resulting to hyper insulinemia and insulin 
resistance (311, 313, 314,). Thus, an increased trend in the protein intake could be one 
possibility of not finding improvement in the glycemic profile of women receiving the 
flaxseed regimens.
Similarly, high intake of total fat and saturated fat also worsens carbohydrate 
metabolism by increasing the production of free fatty acids which in turn compete with 
the glucose uptake by the muscles. Surplus availability of plasma free fatty acids through 
diet accumulates in the adipose tissue and non- adipose tissues such as liver and muscle 
and decreases the intracellular concentration of glucose resulting in hyperglycemia. To 
maintain euglycemic condition, pancreatic beta cells are stimulated to produce excess 
insulin resulting in hyperinsulinemia and finally deteriorating the function of beta cells 
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resulting in insulin-resistance (315-317). Recent literature suggests that it is the quality of 
fat that influences insulin sensitivity and insulin resistance (312) . Many studies have 
demonstrated that intake of saturated fat deteriorates insulin sensitivity and increases 
insulin resistance (318, 319, 320), whereas polyunsaturated fatty acids (PUFA) enhances 
insulin sensitivity (321, 322, 323). It has also been identified that saturated fat is one of 
the most important dietary variables contributing to the progression of type 2 diabetes in 
ethnic populations such as Native Americans (324, 325), Japanese Americans (326), 
Mexican Americans (327). In our study, the high intake of total fat and saturated fat 
might have gone beyond the effect of flaxseed and flaxseed + fiber in the treatment 
groups.  
The glycemic index of plant foods, particularly grains, are lower when they are 
less refined and it is generally believed that incorporation of whole kernels in the baking 
products such as bread and muffins improve their glycemic and insulin profile rather than 
high fiber alone (305). Method of processing such as heating, cooking, baking, size of the 
grain and grain structure (304, 308, 328) may also affect their glycemic index (305). Thus 
baking process may rise the GI of breads and control the post prandial and fasting
glucose levels. However, baking breads at low temperatures for longer time might 
produce better results in controlling glucose by hampering the digestion of bread and 
increasing the formation of resistant starch and retrogradation of amylase (305).
Therefore, processed flaxseed in the form of breads and muffins in our study theoretically 
should have been more effective in reducing glucose and improving insulin levels ground 
flaxseed. However, results from earlier study by  Leininen et al (305) using whole kernel 
rye bread suggest that intact structure of the kernel ruptures during the baking process 
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and gets uncovered to enzymatic hydrolysis of starch. This might be a possibility in our 
study that ground flaxseed during baking process might have been subjected to the above 
mentioned process and resulted in no improvement of the glycemic profile in the 
treatment groups.
As it was discussed earlier, it has been demonstrated that, physical form of food is 
an important factor in controlling glycemic response (329). Jenkins and his colleagues
reported that intake of pasta (white spaghetti) reduced blood glucose level remarkably 
compared to white and whole meal bread.  It was also documented in another study
(330), that white spaghetti and whole meal spaghetti were able to significantly lower 
glycemic responses compared to white bread and Semolina bread. Therefore, many non 
nutrients factors influence the glycemic index of food which in turn affects the glycemic 
profile. Our study might have produced pronounced results, if we had used ground 
flaxseed in conjunction with low glycemic index foods such as pasta, spaghetti rather 
than high glycemic index foods like bread and muffins.
Overall, the findings of our study suggest that intake of 25 to 30 grams of flaxseed
incorporated into baked products by postmenopausal Native American for 3 months can 
sustain their glycemic profile.
Table 1: Nutrition facts of the study products
Bread Muffin Powder
Treatment A B C A B C B C
Serving size 1 slice 1 piece 2 Tbsp
Energy 
(kcal)
70 80 70 150 160 130
Flaxseed (g) - 1.5 1.5 - 5 5
Carbs (g) 12 16 7 25 22 21
Protein (g) 2 3 8 5 4 4
Fat  (g) 1 1 4 4.5 6 4.5







A= Control group, B= Flaxseed group, C= Flaxseed + fiber group. Values are as mentioned on the product labels provided by Natural 
oven of Manitowic,WI.
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Total energy (kcal) 1123± 104 1683± 300 1784 ±684 0.541
Nutrients (g)
Protein 47 ±14 65± 47 59± 25 0.718
Carbohydrates 136± 42 195±106 229±91 0.285
Dietary fiber 13 ±2 18 ±13 16 ±6 0.658
Total fat 45±16 77± 67 74± 31 0.613
Saturated fat 11± 3 23±17 23±11 0.399
Polyunsaturated fat 10± 2 17± 16 17± 8 0.685
Minerals (mg)
Calcium 366 ±129 661± 417 648± 449 0.529
Data represent least square mean + SE. Differences were considered significant at
value <0.05.
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Total energy (kcal) 1511± 193 1994± 161 1967± 161 0.195
Nutrients (g)
Protein 46± 8 67± 5 69± 6 0.074
Carbohydrates 195± 32 252± 26 218± 19 0.325
Dietary fiber 12± 5c 22± 8b 30± 10a 0.000
Total fat 49± 27 78± 24 71± 28 0.062
Saturated fat 12± 3 20 ±2 20± 3 0.099
Polyunsaturated fat 5± 2 8± 1 10± 2 0.230
Minerals (mg)
Calcium 476± 72c 814 ±68a 654± 66b 0.015
Data represent least square mean + SE. Differences were considered significant at 
   P value <0.05.
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Table 4: Subject characteristics and anthropometric measurements








n 17 9 - 20 17 - 18 16
Age, yrs 50.8 ±3.1 - - 57.0±2.2 - - 60.4±2.5 - -
Weight, kg 75.0±5.5 72.1±7.0 0.06 82± 3.6 81.5 ±4.3 0.61 79.1±4.2 78.5 ±4.0 0.51
BMI 28.9±1.9 28.1±1.9 0.17 30.8±1.4 31.1±1.4 0.42 30.8±1.4 30.5±1.4 0.39
Hip* 
inches 42.4 ±1.2 43.3±1.4 0.30 45.2±1.3a 43.8 ±1.5b 0.03 43.5±1.2 42.7 ±1.2 0.16
Waist*, 
inches 36.7± 2.3 36.3± 2.6 0.62 39.8± 1.4a 38.4 ±1.5b 0.01 39.3 ±1.1 39.1 ±1.1 0.60
Waist/ hip 
ratio 0.86 0.83 0.47 0.88 0.88 0.45 0.95 0.91 0.38
Body Fat*, 
% 38.2 ±1.6 35.7 ±2.5 0.20 39.9 ±1.2 39.1 ±1.5 0.56 40.1± 1.4b 43.3± 1.5a 0.02
Fatbody wt 29.2 ±2.3 26.5± 2.6 0.10 33.5 ±1.45 32.7 ±1.5 0.50 32.3 ±1.1 34.2 ±1.1 0.12
Lean Body 
Wt 45.7± 2.7 45.8 ±3.0 0.93 48.8 ±1.7 49.0 ±2.0 0.77 45.6± 2.1 44.9 ±2.6 0.31
Data represent least square mean + SE. Differences were considered significant at P value <0.05. In each groups the values that do not 
share the same superscript letters are significantly different. BMI=Body mass index
55
Table: 5 Effects of three-month flaxseed supplementation on serum glucose parameters in postmenopausal women









































0.12 62.22 14.4±4.20 17.62± 
4.20
0.59 22.36 16.97±4.6 17.14± 
4.8
0.9 1.001







0.13 12.93 5.79± 0.26 5.872± 
0.26





Data represent least square mean + SE. Differences were considered significant at P value <0.05.; n= 9 for control group, n= 17 for 
flaxseed group, n= 16 for flaxseed with additional fiber group. P_A 1c = Percentage Hemoglobin, HOMA-IR= Homeostatic Model 
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